Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;78(7):988-995.
doi: 10.1136/annrheumdis-2018-215004. Epub 2019 Apr 24.

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis

Sara Sabbagh #  1 , Iago Pinal-Fernandez #  1   2   3 , Takayuki Kishi  4 , Ira N Targoff  5 , Frederick W Miller  4 , Lisa G Rider #  4 , Andrew Lee Mammen #; Childhood Myositis Heterogeneity Collaborative Study Group
Affiliations

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis

Sara Sabbagh et al. Ann Rheum Dis. 2019 Jul.

Abstract

Objectives: Anti-Ro52 autoantibodies are associated with more severe interstitial lung disease (ILD) in adult myositis patients with antiaminoacyl transfer (t)RNA synthetase autoantibodies. However, few studies have examined anti-Ro52 autoantibodies in juvenile myositis. The purpose of this study was to define the prevalence and clinical features associated with anti-Ro52 autoantibodies in a large cohort of patients with juvenile myositis.

Methods: We screened sera from 302 patients with juvenile dermatomyositis (JDM), 25 patients with juvenile polymyositis (JPM) and 44 patients with juvenile connective tissue disease-myositis overlap (JCTM) for anti-Ro52 autoantibodies by ELISA. Clinical characteristics were compared between myositis patients with and without anti-Ro52 autoantibodies.

Results: Anti-Ro52 autoantibodies were found in 14% patients with JDM, 12% with JPM and 18% with JCTM. Anti-Ro52 autoantibodies were more frequent in patients with antiaminoacyl tRNA synthetase (64%, p<0.001) and anti-MDA5 (31%, p<0.05) autoantibodies. After controlling for the presence of myositis-specific autoantibodies, anti-Ro52 autoantibodies were associated with the presence of ILD (36% vs 4%, p<0.001). Disease course was more frequently chronic, remission was less common, and an increased number of medications was received in anti-Ro52 positive patients.

Conclusions: Anti-Ro52 autoantibodies are present in 14% of patients with juvenile myositis and are strongly associated with anti-MDA5 and antiaminoacyl tRNA synthetase autoantibodies. In all patients with juvenile myositis, those with anti-Ro52 autoantibodies were more likely to have ILD. Furthermore, patients with anti-Ro52 autoantibodies have more severe disease and a poorer prognosis.

Keywords: anti-ro52 autoantibodies; interstitial lung disease; juvenile idiopathic inflammatory myopathies; myositis; myositis associated autoantibodies.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1.
Figure 1.. Swarm plot of anti-Ro52 autoantibody ELISA results for juvenile healthy controls and JIIM patients divided into JDM, JPM, and JCTM.
The dashed line of 20 units indicates the cut-off value for anti-Ro52 autoantibody positivity. Out of 371 JIIM patients, 53 (14%) were positive for anti-Ro52 autoantibodies by ELISA. Of these patients, 42 had JDM, 3 had JPM, and 8 had JCTM. Out of 90 juvenile healthy controls, one patient (1.1%) was positive for anti-Ro52 autoantibodies by ELISA.
See this image and copyright information in PMC

Comment in

References

    1. Pachman LM, Khojah AM. Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity. J Pediatr 2018;195:16–27. doi: 10.1016/j.jpeds.2017.12.053 [published Online First: 2018/03/27] - DOI - PMC - PubMed
    1. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 2013;92(4):223–43. doi: 10.1097/MD.0b013e31829d08f9 [published Online First: 2013/07/24] - DOI - PMC - PubMed
    1. Rider LG, Nistala K. The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes. J Intern Med 2016;280(1):24–38. doi: 10.1111/joim.12444 [published Online First: 2016/03/31] - DOI - PMC - PubMed
    1. Sakurai N, Nagai K, Tsutsumi H, et al. Anti-CADM-140 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and cardiac involvement. J Rheumatol 2011;38(5):963–4. doi: 10.3899/jrheum.101220 [published Online First: 2011/05/03] - DOI - PubMed
    1. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res Ther 2014;16(4):R138. doi: 10.1186/ar4600 [published Online First: 2014/07/06] - DOI - PMC - PubMed

Publication types